Suppr超能文献

接受体外膜肺氧合治疗的患者发生的血流感染

Bloodstream infections in patients undergoing extracorporeal membrane oxygenation.

作者信息

Wang Jian-Rong, Huang Jin-Yu, Hu Wei, Cai Xue-Ying, Hu Wei-Hang, Zhu Ying

机构信息

Jian-rong Wang, MS. Department of Critical Care Medicine, The Affiliated Hangzhou Hospital of Nanjing Medical University, Zhejiang, China.

Jin-yu Huang, MD. Department of Cardiology, The Affiliated Hangzhou Hospital of Nanjing Medical University, Zhejiang, China.

出版信息

Pak J Med Sci. 2020 Sep-Oct;36(6):1171-1176. doi: 10.12669/pjms.36.6.2882.

Abstract

OBJECTIVE

We aimed to evaluate the incidence, risk factors, and prognosis of bloodstream infections (BSIs) during extracorporeal membrane oxygenation (ECMO) treatment in a Chinese population.

METHODS

Patients receiving ECMO treatment from January 2013 to August 2019 were retrospectively studied. The incidence of BSIs was calculated. The clinical characteristics between patients with a BSI (BSI group) and without a BSI (non-BSI group).

RESULTS

Among 69 included patients, 19 (27.5%) developed at least one BSI. Gram-negative bacteria (73.7%) were mainly responsible for the BSIs, with (6/19, 31.5%) ranking as the top related pathogen. The BSI group had a greater proportion of methicillin-resistant (MRSA) prophylactic regimens (52.6% vs. 26.0%, P = 0.036), a higher pre-ECMO Sequential Organ Failure Assessment (SOFA) score (11 vs. 8, P = 0.008), more applications of continuous renal replacement therapy (CRRT) during ECMO (63.1% vs. 36.1%, P = 0.042). Longer ECMO support duration, period of ventilator use before ECMO weaning and hospital stay were observed in the BSI group. The SOFA score (OR: 1.174; 95% CI: 1.039-1.326; P = 0.010) was an independent risk factor for BSIs.

CONCLUSION

BSIs during ECMO therapy frequently involve Gram-negative bacteria. Stringent care and monitoring should be provided for patients with high SOFA scores.

摘要

目的

我们旨在评估中国人群体外膜肺氧合(ECMO)治疗期间血流感染(BSIs)的发生率、危险因素及预后。

方法

回顾性研究2013年1月至2019年8月接受ECMO治疗的患者。计算BSIs的发生率。比较发生BSIs的患者(BSI组)和未发生BSIs的患者(非BSI组)的临床特征。

结果

在纳入的69例患者中,19例(27.5%)发生了至少一次BSIs。革兰氏阴性菌(73.7%)是BSIs的主要致病菌,其中[具体细菌名称未给出](6/19,31.5%)为最主要相关病原体。BSI组耐甲氧西林[具体细菌名称未给出](MRSA)预防性治疗方案的比例更高(52.6%对26.0%,P = 0.036),ECMO前序贯器官衰竭评估(SOFA)评分更高(11对8,P = 0.008),ECMO期间连续肾脏替代治疗(CRRT)的应用更多(63.1%对36.1%,P = 0.042)。BSI组的ECMO支持时间更长,ECMO撤机前呼吸机使用时间和住院时间更长。SOFA评分(OR:1.174;95%CI:1.039 - 1.326;P = 0.010)是BSIs的独立危险因素。

结论

ECMO治疗期间的BSIs常涉及革兰氏阴性菌。对于SOFA评分高的患者应给予严格的护理和监测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad7f/7501021/a74e95988820/PJMS-36-1171-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验